JSJ Pharmaceuticals

JSJ Pharmaceuticals was a specialty pharmaceutical company based in Charleston, South Carolina, that focused on the dermatology and pain management markets. The company specialized in the commercialization of branded prescription products, utilizing a targeted sales force to reach dermatologists and pain specialists. Its portfolio featured several FDA-approved treatments, including the topical anesthetic Pliaglis, the acne medication NeoBenz Micro, and the radiation dermatitis treatment Xclair. JSJ's business model involved acquiring or licensing late-stage assets to build a niche therapeutic presence. In 2011, the company's flagship product, Pliaglis, was acquired by Galderma, leading to the eventual wind-down of JSJ's independent operations.